Subtenon carboplatin in the management of intraocular retinoblastoma
Iranian Journal of Ophthalmic Research. 2006; 1 (1): 23-30
in English
| IMEMR
| ID: emr-76989
ABSTRACT
To evaluate the efficacy of subtenon carboplatin as an adjuvant to systemic chemotherapy in the management of intraocular retinoblastoma. This study was conducted as a randomized, double-masked clinical trial. A diagnosis of intraocular retinoblastoma was made based on clinical examination, ultrasonography and orbital CT-scanning. The greatest basal dimension of the tumors was estimated in disc diameter [DD] by indirect ophthalmoscopy. Tumor thickness was determined by ultrasonography. Each eye was assigned to one of 10 blocks based on tumor stage [Reese-Ellseworth classification] and randomly received systemic chemotherapy alone [control group] or systemic chemotherapy plus 20mg subtenon carboplatin [case group]. Indirect laser photocoagulation or cryotherapy was performed as additional treatment. The study included 35 tumors in 17 eyes of 14 patients [19 tumors in 8 eyes of the control group and 16 tumors in 9 eyes of the case group]. There was 57.22% and 61.73% decrease in tumor thickness in the control and case groups, respectively [P=0.12]. The decrease in greatest basal tumor dimension in the control group [47.32%] was not significantly different from that in the case group [38.80%]. One eye [12.5%] in the control group and 3 eyes [33.3%] in the case group were enucleated. Adjuvant subtenon carboplatin does not seem to increase the efficacy of systemic chemotherapy in the treatment of intraocular retinoblastoma
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Main subject:
Randomized Controlled Trials as Topic
/
Double-Blind Method
/
Carboplatin
/
Disease Management
/
Retinal Neoplasms
/
Antineoplastic Agents
Type of study:
Controlled clinical trial
Limits:
Female
/
Humans
/
Male
Language:
English
Journal:
Iran. J. Ophthalmic Res.
Year:
2006
Similar
MEDLINE
...
LILACS
LIS